Malignant Tumor Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Malignant Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 2

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Breast CancerBreast CarcinomaBreast Neoplasm+34 more
University of California, Davis86 enrolled1 locationNCT06268665
Recruiting
Phase 1Phase 2

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379
Recruiting
Not Applicable

Histotripsy for Ablation of Liver Tumours in Asia

Liver Malignant Tumors
National Cancer Centre, Singapore40 enrolled3 locationsNCT07428356
Recruiting
Phase 1Phase 2

Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease

Malignant TumorHyperthyroidism, AutoimmuneCardiovascular Abnormalities
Peking Union Medical College Hospital600 enrolled1 locationNCT07400224
Recruiting
Phase 1Phase 2

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Ovarian CarcinomaNSCLCSCLC+5 more
Jacobio Pharmaceuticals Co., Ltd.152 enrolled1 locationNCT04686682
Recruiting
Not Applicable

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Pancreatic CancerMelanomaLiver Malignant Tumors+1 more
M.D. Anderson Cancer Center60 enrolled1 locationNCT05053555
Recruiting
Phase 1Phase 2

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Epithelioid SarcomaAtypical Teratoid/Rhabdoid TumorChordoma+4 more
Susan Chi, MD49 enrolled3 locationsNCT05407441
Recruiting
Not Applicable

High-Resolution PET-CT Imaging for Surgical Margin Visualization

CancerHNSCCSCC - Squamous Cell Carcinoma+2 more
Vanderbilt-Ingram Cancer Center50 enrolled1 locationNCT06915454
Recruiting
Phase 1Phase 2

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Solid TumorGynecological Malignant Tumor
Sichuan Baili Pharmaceutical Co., Ltd.38 enrolled1 locationNCT05803018
Recruiting
Not Applicable

Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors

Malignant Tumor of Soft Tissue of Head, Face and Neck
Masaryk Memorial Cancer Institute60 enrolled1 locationNCT03751566
Recruiting

Psychological Distress in Malignant Tumor Patients: Effects on Treatment Adherence, Outcomes, and Quality of Life

Psychological DistressMalignant Tumor
Gang Chen, MD2,000 enrolled1 locationNCT07193329
Recruiting

Molecular Basis of Pediatric Liver Cancer

Hepatocellular CarcinomaLiver Malignant TumorsHepatoblastoma+3 more
University of Pittsburgh1,600 enrolled1 locationNCT03959800
Recruiting
Phase 1Phase 2

A Beta-only IL-2 ImmunoTherapY Study

Triple-Negative Breast CancerEsophageal CancerGastric Cancer+34 more
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting

High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy

Prostate CancerRadiotherapy; ComplicationsBrachytherapy+2 more
Clinica Universidad de Navarra, Universidad de Navarra20 enrolled1 locationNCT06982469
Recruiting
Phase 1

First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours

Advanced Solid TumorMetastatic CancerGlioblastoma Multiforme+1 more
Phost'In Therapeutics149 enrolled4 locationsNCT05495295
Recruiting

Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors

Kidney TumorRenal Malignant TumorRenal Benign Neoplasm
Loyola University100 enrolled1 locationNCT05728957
Recruiting
Phase 2

Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy

RadiotherapyLocal Recurrence of Malignant Tumor of Prostate
Maria Sklodowska-Curie National Research Institute of Oncology55 enrolled1 locationNCT06201078
Recruiting
Phase 2

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Hepatocellular CarcinomaMelanomaEsophageal Adenocarcinoma+5 more
Dan Zandberg72 enrolled1 locationNCT04114136
Recruiting
Phase 1Phase 2

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Breast CancerCancer of the BreastBreast Tumor+3 more
BriaCell Therapeutics Corporation18 enrolled1 locationNCT06471673
Recruiting
Phase 1Phase 2

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Small Cell Lung CancerAdvanced Solid Malignant Tumor
Chipscreen Biosciences, Ltd.36 enrolled11 locationsNCT05271292